Prestige Consumer Healthcare (PBH) Set to Post Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to be releasing its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect Prestige Consumer Healthcare to announce earnings of $1.07 per share and revenue of $329.15 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same quarter in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $4.56 EPS for the current fiscal year and $5.09 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Up 0.9%

PBH stock opened at $47.81 on Thursday. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 1.50 and a beta of 0.34. The company has a fifty day moving average price of $48.63 and a 200 day moving average price of $54.36. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare has a 12 month low of $42.62 and a 12 month high of $71.07.

Analyst Ratings Changes

A number of research firms have commented on PBH. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 30th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $67.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.